Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs used in the treatment of type 2 diabetes mellitus (T2DM). Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment-related AEs for GLP-1 RAs. We aim to evaluate the effect of GLP...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Technol Ther
Hlavní autoři: Sun, Feng, Chai, Sanbao, Yu, Kai, Quan, Xiaochi, Yang, Zhirong, Wu, Shanshan, Zhang, Yuan, Ji, Linong, Wang, Jun, Shi, Luwen
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc. 2015
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4290796/
https://ncbi.nlm.nih.gov/pubmed/25375397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2014.0188
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky